Skip to main content

Vertex Pharmaceuticals company profile

  • VRTX · Nasdaq
  • Pharmaceuticals
  • Biotechnology
  • S&P 500
$538.60−0.74%Close 13 Nov 2026

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers, develops, and commercializes medicines for serious diseases, with a focus on specialty markets. Its approved products treat cystic fibrosis, with five CFTR modulator medicines marketed in more than 60 countries; severe sickle cell disease and transfusion dependent beta thalassemia, through the gene-editing therapy CASGEVY, available in the U.S., Europe, Canada, and the Middle East; and acute pain, through JOURNAVX, approved in the U.S. The company sells primarily to specialty pharmacies and distributors, major U.S. wholesalers, and hospitals and clinics outside the U.S., and promotes its medicines directly to healthcare professionals. Its clinical pipeline includes programs in kidney diseases, type 1 diabetes, neuropathic pain, and myotonic dystrophy type 1.

A summary of the business section of the company's latest annual report, filed 13 Feb 2026.

Company facts

TickerVRTX · Nasdaq
SectorPharmaceuticals
IndustryBiotechnology
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK875320
Latest annual report10-K, filed 13 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Bruce I. SachsDirector94.5K · < 1%Gift, 27 Aug 2026
Stuart A. ArbuckleEVP, COO68.5K · < 1%Shares withheld for tax, 1 Jul 2025
Amit SachdevEVP Chief Patient & Ext Af Off48.5K · < 1%Grant or award, 21 Jul 2026
Reshma KewalramaniCEO &amp; President · Director47.8K · < 1%Sale under a 10b5-1 plan, 6 Nov 2026
Alan GarberDirector37.6K · < 1%Grant or award, 1 May 2026
Jeffrey M. LeidenExecutive Chairman · Director35.2K · < 1%Shares withheld for tax, 24 Feb 2026
Charles F. Wagner, Jr.EVP, CO & FO27.7K · < 1%Shares withheld for tax, 24 Feb 2026
Carmen BozicEVP and CMO25.5K · < 1%Sale under a 10b5-1 plan, 26 Jun 2026
Diana McKenzieDirector9.4K · < 1%Disposition to the issuer, 1 May 2026
Lloyd CarneyDirector6.3K · < 1%Gift, 19 Nov 2025
Suketu UpadhyayDirector5.1K · < 1%Disposition to the issuer, 1 May 2026
Nancy ThornberryDirector4.8K · < 1%Grant or award, 1 May 2026
Sangeeta N. BhatiaDirector4.3K · < 1%Sale under a 10b5-1 plan, 4 May 2026
Jennifer SchneiderDirector1.7K · < 1%Disposition to the issuer, 1 May 2026
Brennan Daniel J.Director—Grant or award, 20 Oct 2026
van Grunsven JasperEVP, CP and NPPO—Grant or award, 8 Sep 2026
Ambrose KristenSVP & Chief Accounting Officer—Grant or award, 28 Aug 2026
Tatsis OuraniaEVP, Chief Reg. & Quality Off.—Grant or award, 21 Jul 2026
McKechnie DuncanEVP, Chief Commercial Officer—Sale under a 10b5-1 plan, 2 Jul 2026
Liu JoyEVP and Chief Legal Officer—Sale under a 10b5-1 plan, 1 Jul 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

VRTX in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.